HR 597 117th Congress House Health Business records Cardiovascular and respiratory health Civil actions and liability Drug safety, medical device, and laboratory regulation Drug therapy Emergency medical services and trauma care Fraud offenses and financial crimes Government information and archives Health care costs and insurance Health programs administration and funding Health promotion and preventive care Health technology, devices, supplies Immunology and vaccination Income tax credits Infectious and parasitic diseases Inflation and prices Intellectual property Manufacturing Medical tests and diagnostic methods

Pandemic Treatment Access and Affordability Act of 2021

Introduced: January 28, 2021 Introduced by: Schakowsky, Janice D. Democratic · Illinois See on congress.gov

Everywhere this bill has been 4 steps

Introduced

In committee

Reported out

Passed House

Passed Senate

To President

Became law

Mar 22, 2021

Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Feb 2, 2021

Referred to the Subcommittee on Health.

Jan 28, 2021

Referred to the Committee on Energy and Commerce, and in addition to the Committees on the Judiciary, Science, Space, and Technology, and Armed Services, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Jan 28, 2021

Introduced in House

Plain-English summary Congressional Research Service

Pandemic Treatment Access and Affordability Act of 2021

This bill imposes licensing and price restrictions on federally supported drugs and other medicines intended to address COVID-19 (i.e., coronavirus disease 2019) or other public health emergencies.

With respect to a COVID-19 drug patent developed using certain types of federal support, any license granted by the federal government shall be open and nonexclusive. Similarly, a licensee or assignee for such a patent shall grant open nonexclusive licenses for the patent. An entity that receives a license shall pay reasonable royalties to (1) the patent holder, or (2) the owner of marketing exclusivity rights granted by the Food and Drug Administration (FDA) that were terminated under this bill.

The bill requires that such drugs be offered at a fair and reasonable price based on certain considerations, such as access.

If the Department of Health and Human Services (HHS) finds that the price of any drug to address a public health emergency is excessive, HHS must void any FDA-granted exclusivity for the drug and grant open and nonexclusive licenses to other manufacturers. Such licenses are subject to reasonable royalty requirements.

What's happening now March 22, 2021

Referred to the Subcommittee on Courts, Intellectual Property, and the Internet.

Committees of jurisdiction 6